Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Locally Advanced or Metastatic Urothelial Cell Carcinoma Clear all
Approved For Marketing No phase listed Expanded access

An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma

NCT04136808
View directory record Official record
Conditions
Locally Advanced or Metastatic Urothelial Carcinoma (UC)
Interventions
enfortumab vedotin (EV)
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
15
States / cities
Los Angeles, California • Santa Monica, California • Santa Rosa, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Jul 23, 2026, 2:24 PM EDT
Recruiting Phase 1 Interventional

A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

NCT04969835
View directory record Official record
Conditions
Salivary Gland Tumor, Urothelial Carcinoma, Ovarian Carcinoma, Breast Cancer, Soft Tissue Sarcoma
Interventions
AVA6000
Drug
Lead sponsor
Avacta Life Sciences Ltd
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
New York, New York • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 23, 2026, 2:24 PM EDT
Terminated Phase 2 Interventional Results available

Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab

NCT04887831
View directory record Official record
Conditions
Urothelial Carcinoma, Bladder Cancer, Myelosuppression Adult, Chemotherapy-induced Neutropenia, Metastatic Bladder Cancer
Interventions
Trilaciclib, Gemcitabine, Cisplatin, Carboplatin, Avelumab
Drug
Lead sponsor
G1 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Los Angeles, California • Whittier, California • Littleton, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Jul 23, 2026, 2:24 PM EDT
Completed Phase 3 Interventional Results available

A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)

NCT02603432
View directory record Official record
Conditions
Urothelial Cancer
Interventions
Avelumab, Best Supportive Care, Following the planned interim analysis for this study: Avelumab
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
19
States / cities
Aurora, Colorado • New Haven, Connecticut • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Jul 23, 2026, 2:24 PM EDT
Recruiting Phase 1Phase 2 Interventional

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

NCT07038343
View directory record Official record
Conditions
Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Lung Cancers, Epithelial Tumor, Biliary Tract Cancer (BTC), Urothelial Cancer, Nasopharyngeal Cancers
Interventions
AVZO-1418, Combination Agent 1, Combination Agent 2
Drug
Lead sponsor
Avenzo Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
18
States / cities
Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jul 23, 2026, 2:24 PM EDT
Terminated Phase 2 Interventional Results available

A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy

NCT03029832
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
MOXR0916, Atezolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
15
States / cities
Tucson, Arizona • Denver, Colorado • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Jul 23, 2026, 2:24 PM EDT
Terminated Early Phase 1 Interventional

Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors

NCT03454243
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors
Interventions
RXDX-106
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Jul 23, 2026, 2:24 PM EDT
Completed Phase 1Phase 2 Interventional

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

NCT04666688
View directory record Official record
Conditions
Metastatic Cancer, Solid Tumor, Pancreatic Cancer, Urothelial Carcinoma, Head and Neck Cancer, Colorectal Cancer
Interventions
LYT-200, Tislelizumab, Gemcitabine/nab-paclitaxel
Drug
Lead sponsor
PureTech
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Sarasota, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Jul 23, 2026, 2:24 PM EDT
Recruiting Phase 2 Interventional

Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma

NCT07043972
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Gemcitabine, Carboplatin
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Jul 23, 2026, 2:24 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

NCT03582475
View directory record Official record
Conditions
Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Prostate Carcinoma Metastatic in the Bone, Prostate Neuroendocrine Neoplasm, Prostate Small Cell Carcinoma, Stage III Bladder Cancer American Joint Committee on Cancer ( AJCC) v8, Stage III Prostate Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Ureter Small Cell Carcinoma, Urothelial Carcinoma
Interventions
Carboplatin, Cisplatin, Docetaxel, Etoposide, Pembrolizumab
Drug · Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Jul 23, 2026, 2:24 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma

NCT03123055
View directory record Official record
Conditions
Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease, Urological Diseases
Interventions
B-701, Pembrolizumab
Drug
Lead sponsor
Rainier Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Greenbrae, California • Fort Wayne, Indiana • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Jul 23, 2026, 2:24 PM EDT
Terminated Phase 1Phase 2 Interventional

A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

NCT03288545
View directory record Official record
Conditions
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms, Urothelial Cancer, Ureteral Neoplasms, Urethral Neoplasms
Interventions
enfortumab vedotin (EV), pembrolizumab, cisplatin, carboplatin, gemcitabine
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
83
States / cities
Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Jul 23, 2026, 2:24 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer

NCT02426125
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Ramucirumab, Docetaxel, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
33
States / cities
Fayetteville, Arkansas • Fullerton, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Jul 23, 2026, 2:24 PM EDT
Completed Phase 1 Interventional Results available

Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566

NCT02315066
View directory record Official record
Conditions
Neoplasms
Interventions
PF-04518600, PF-04518600 plus PF-05082566
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
24
States / cities
Los Angeles, California • Newport Beach, California • Santa Monica, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Jul 23, 2026, 2:24 PM EDT
Completed Phase 1 Interventional Results available

A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors

NCT02573259
View directory record Official record
Conditions
Part 1, MELANOMA, SCCHN, OVCA, SARCOMA, OTHER SOLID TUMORS, Part 1 and 2, NSCLC, UROTHELIAL CARCINOMA
Interventions
PF-06801591
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
24
States / cities
Los Angeles, California • Santa Monica, California • Louisville, Kentucky + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2021 · Synced Jul 23, 2026, 2:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors

NCT02983045
View directory record Official record
Conditions
Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Triple Negative Breast Cancer, HR+/HER2- Breast Cancer, Gastric Cancer
Interventions
Dose Escalation Doublet: Combination of NKTR-214 + nivolumab, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab, Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
22
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2023 · Synced Jul 23, 2026, 2:24 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

NCT05267626
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
Interventions
AU-007, Aldesleukin, Avelumab, Nivolumab
Drug
Lead sponsor
Aulos Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
11
States / cities
Miami, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 8 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 23, 2026, 2:24 PM EDT
Completed Phase 1 Interventional

SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)

NCT04291079
View directory record Official record
Conditions
Cancer
Interventions
SRK-181, anti-PD-(L)1 antibody therapy
Biological
Lead sponsor
Scholar Rock, Inc.
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
18
States / cities
Fullerton, California • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jul 23, 2026, 2:24 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

NCT04856189
View directory record Official record
Conditions
Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Urothelial Carcinoma
Interventions
Pembrolizumab, Selinexor
Biological · Drug
Lead sponsor
Mamta Parikh
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jul 23, 2026, 2:24 PM EDT
Recruiting Phase 1 Interventional

Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

NCT04878029
View directory record Official record
Conditions
Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Interventions
Cabozantinib S-malate, Enfortumab Vedotin, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jul 23, 2026, 2:24 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction

NCT00365157
View directory record Official record
Conditions
Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7, Unresectable Urothelial Carcinoma
Interventions
Eribulin Mesylate, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2026
U.S. locations
26
States / cities
Beverly Hills, California • Duarte, California • Lancaster, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Jul 23, 2026, 2:24 PM EDT
Terminated Phase 2 Interventional Results available

Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

NCT03397394
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Renal Pelvis Carcinoma, Ureter Carcinoma, Urinary Bladder Carcinoma, Urethra Carcinoma, Muscle Invasive Bladder Cancer
Interventions
Rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
41
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Jul 23, 2026, 2:24 PM EDT
Active, not recruiting Phase 1 Interventional

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

NCT03821935
View directory record Official record
Conditions
Advanced Solid Tumors Cancer
Interventions
Livmoniplimab, Budigalimab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
21
States / cities
Springdale, Arkansas • Duarte, California • Irvine, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Jul 23, 2026, 2:24 PM EDT
Terminated Phase 1 Interventional

Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract

NCT02925533
View directory record Official record
Conditions
Bladder Cancer
Interventions
B-701, Pembrolizumab
Drug
Lead sponsor
Mark Pomerantz, MD
Other
Eligibility
18 Years to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Jul 23, 2026, 2:24 PM EDT